Day One to Participate in the Cowen 42nd Annual Health Care Conference

Rhea-AI Summary

Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company, has announced its participation in a fireside chat at the Cowen 42nd Annual Health Care Conference on March 7 at 2:50 p.m. ET. A live audio webcast of the chat will be accessible on the company’s website, with a replay available for 30 days.

The company specializes in targeted therapies for life-threatening diseases, highlighting its lead product candidate, DAY101, which is currently in a pivotal Phase 2 trial for low-grade glioma in younger patients.

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced management will participate in a fireside chat at the Cowen 42^nd Annual Health Care Conference on Monday, March 7 at 2:50 p.m. ET.

A live audio webcast of the discussion will be available by visiting the Events & Presentations section of the Company’s website. An archived replay of the webcast will be available for 30 days following the live presentation.

About Day One Biopharmaceuticals
Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases. Day One partners with leading clinicians, families, and scientists to identify, acquire, and develop important emerging targeted treatments. The Company’s lead product candidate, DAY101 (tovorafenib), is an oral, highly-selective type II pan-RAF kinase inhibitor currently being evaluated in a pivotal Phase 2 clinical trial (FIREFLY-1) in pediatric, adolescent and young adult patients with recurrent or progressive low-grade glioma (pLGG). The Company’s pipeline also includes the investigational agent pimasertib, a clinical-stage, oral, small molecule found to selectively inhibit mitogen-activated protein kinases 1 and 2 (MEK), which will be evaluated in a Phase 1/2 study (FIRELIGHT-1) in combination with DAY101 (tovorafenib) for adult and adolescent patients with solid tumors with MAPK pathway aberrations. Day One is based in South San Francisco. For more information, please visit https://dayonebio.com/.

Contacts:

Media:
1AB
Dan Budwick
dan@1abmedia.com

Investors:
LifeSci Advisors
Hans Vitzthum
hans@lifesciadvisors.com

FAQ

What is the date and time of Day One Biopharmaceuticals' participation in the Cowen 42nd Annual Health Care Conference?

Day One Biopharmaceuticals will participate in the conference on March 7 at 2:50 p.m. ET.

Where can I find the live audio webcast for Day One Biopharmaceuticals' fireside chat?

The live audio webcast will be available on the Events & Presentations section of Day One Biopharmaceuticals' website.

How long will the replay of Day One Biopharmaceuticals' webcast be available?

The archived replay of the webcast will be available for 30 days following the live presentation.

What is the main focus of Day One Biopharmaceuticals?

Day One Biopharmaceuticals is dedicated to developing targeted therapies for life-threatening diseases.

What is DAY101 and what clinical trial is it currently involved in?

DAY101 (tovorafenib) is an oral pan-RAF kinase inhibitor, currently being evaluated in a pivotal Phase 2 clinical trial for low-grade glioma in pediatric and young adult patients.